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ABSTRACT
Background. The rising incidence of incidental thyroid
carcinoma (ITC) detected during fluoro-2-deoxy-D-glucose
(FDG)-positron emission tomography (PET)/computed
tomography (CT) scanning poses a challenge to clinicians.
The present study aims to critically evaluate the clinicopath-
ological characteristics of ITC detected by FDG-PET/CT.
Methods. Among the 557 patients managed at our insti-
tution, 40 (7.2%) patients were identified as having ITC. Of
these, 22 patients had their tumor detected by FDG-PET/
CT (PET group) and 11 by ultrasonography (USG group).
Additional bedside ultrasonography ± fine-needle aspira-
tion (FNA) was done in all patients at their clinic visit. The
clinicopathological characteristics were compared between
the PET and USG groups.
Results. The PET group had significantly more patients
with history of nonthyroidal malignancy (P \ 0.001).
Papillary carcinoma was the most common histological
type in both groups. Despite having similar histological and
prognostic features including tumor size, tumor multifo-
cality, capsular invasion, extrathyroidal extension, and
lymph node metastases, tumor bilaterality (or presence of
contralateral tumor focus) was significantly more frequent
in the PET than the USG group (P = 0.04). The tumors
were also more advanced by the tumor–node–metastasis
(TNM) staging system in the PET group (P = 0.021).
None of the contralateral tumor foci were evident preop-
eratively. One patient in the USG group developed
metastatic thyroid carcinoma in neck lymph nodes
28 months after thyroid resection.
Conclusion. ITC by FDG-PET/CT had higher incidence
of tumor bilaterality than those detected by ultrasonogra-
phy. Total thyroidectomy should be considered for ITC
detected by FDG-PET/CT even for tumor size \10 mm.
Thyroid carcinoma is the most common endocrine tumor
and has generally been associated with favorable prognosis.
Its incidence has almost doubled over the last two decades
in our locality, and a similar trend has also been observed
elsewhere in the world.1,2 However, this major increase
might be owing to increased detection of incidental thyroid
carcinomas (ITC) rather than clinically detected carcino-
mas, as the overall disease-related mortality has not
changed significantly over this period.3 ITC is defined as a
carcinoma incidentally identified by imaging study per-
formed for reason(s) unrelated to the thyroid gland.4
In addition to ultrasonography (USG), computed tomog-
raphy (CT), and magnetic resonance imaging (MRI),
2-[18F]fluoro-2-deoxy-D-glucose (FDG) positron emission
tomography (PET) has become an increasingly important
imaging modality in detecting ITC.5–9 The integrated FDG-
PET/CT system allows better anatomical localization of the
lesion when using the PET/CT fusion image.10 FDG-PET/
CT has become an established imaging tool in oncology as
well as some branches of medicine.11,12 As a result, now-
adays, clinicians are being faced with an increasing number
of ITC detected during FDG-PET/CT scanning. In addition
to localizing a disease process, FDG-PET/CT has been
shown useful in discriminating normal from abnormal dis-
ease processes based on measuring FDG uptake rate
differences.13 Some studies have had some success in dis-
criminating benign from malignant conditions in the
thyroid gland as well as predicting the biological
behavior and tumor aggressiveness of primary thyroid
malignancy by measuring the maximum standardized uptake
value (SUVmax).
6,14–19 When these FDG-avid tumors were
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correlated with histology, they tended to be less well
differentiated and had more aggressive histological fea-
tures.20,21 However, these studies have mainly focused on
nonincidental or clinically significant carcinomas and their
metastases, which probably represent a later stage of the
disease.22 To our knowledge, no study has specifically
evaluated the clinicopathological characteristics of ITC
detected by FDG-PET/CT. To allow more meaningful
evaluation, this study uses a control group consisting of
ITC detected by USG over the same study period.
PATIENTS AND METHODS
From January 2000 to December 2009, a total of 557
patients with thyroid carcinoma were managed at our insti-
tution. Among them, 40 patients (7.2%) had thyroid
incidentaloma which was later confirmed to be malignant
(i.e., ITC). ITC was defined as a carcinoma incidentally
discovered by an imaging modality initially for the purpose
of a nonthyroidal condition. None had known history of
thyroid cancer, hyperthyroidism, hypothyroidism, thyroid-
itis, thyroxine replacement or direct external head and neck
irradiation. Imaging modalities comprised USG, CT, MRI,
and FDG-PET/CT. Patients with ITC detected by CT
(n = 6) or MRI (n = 1) were excluded. There were a total of
33 patients for analysis. Of the 33 patients, 22 (66.7%) had
their tumors detected by FDG-PET/CT (PET group) while 11
(33.3%) had their tumors detected by USG (USG group). All
patients were operated on and managed by the same team of
endocrine surgeons. Tumor specimens were examined by the
same group of expert pathologists at our institution, and no
changes in method of sectioning or pathological examination
were made over the study period. In terms of clinical man-
agement, all patients underwent a bedside USG examination
at their first clinic visit for the purpose of assessing the
presence, location, and appearance of the thyroid incident-
aloma in the ipsilateral and contralateral lobes as well as
possible lymph node enlargement in the central (or level VI)
compartment. This was followed by a fine-needle aspiration
(FNA) performed under USG guidance if the incidentaloma
was C1 cm in diameter or \1 cm but with suspicious fea-
tures such as taller-than-wide, macro- or microcalcifications,
irregular margins, and marked hypoechogenicity.23 These
criteria were applied to all patients regardless of the number
of incidentalomas found. If none of the incidentalomas
looked suspicious and \1 cm, the largest or dominant one
was generally biopsied. FNA was also performed for suspi-
cious cervical lymph nodes. FNA cytology result was
categorized into four broad groups: benign, malignant,
indeterminate (follicular lesion, Hu¨rthle cell lesion, suspi-
cious of malignancy), and inadequate/insufficient.
For those with indeterminate lesions, hemithyroidectomy
was considered sufficient. For subcentimeter differentiated
thyroid carcinoma (DTC) after hemithyroidectomy, the
decision for completion total thyroidectomy was made based
on patient preference. Total thyroidectomy was the preferred
procedure for all patients with malignant FNA cytology
regardless of tumor size. Prophylactic central neck dissec-
tion (CND) (i.e., removal of clinically normal lymph nodes)
was not routinely performed, but if there were clinically
enlarged lymph nodes, CND would be performed. Lateral
neck dissection was performed for patients with either clin-
ical or ultrasonic evidence of lymph node metastases before
surgery. Details on the management protocol for thyroid
carcinoma were described previously.24 Final histological
findings and pathological tumor staging based on the
American Joint Committee on Cancer (AJCC)/International
Union against Cancer (UICC) 6th edition were recorded.
Tumor multifocality was defined as the presence of[1 tumor
focus in the ipsilateral lobe of the primary tumor or in the
contralateral lobe. Tumor bilaterality was defined as the
presence of at least one other tumor focus in the contralateral
lobe of the primary tumor. Bilateral disease by definition was
multifocal.
FDG-PET/CT
Although not all 22 patients had FDG-PET/CT performed
at our own institution, the preparation and scanning tech-
nique were similar. All patients were asked to fast for a
minimum of 6 h, and serum glucose level was confirmed as
less than 120 mg/dL before intravenous (IV) administration
of 370–555 MBq FDG through a peripheral vein. After
60 min, PET images were acquired using a full-ring dedi-
cated PET scanner. Whole-body PET/CT studies were
obtained by using a 64-detector CT system. Thyroid pattern
of FDG uptake was classified as either focal or diffuse. Focal
pattern was defined as one focus of uptake within one lobe,
whereas diffuse pattern was defined as at least one focus each
in both lobes. The site of focal uptake, the SUVmax of the
thyroid lesion, and other sites of FDG uptake were recorded
and correlated with both clinical and final histological
findings.
Statistical Analysis
Statistical analysis was performed using the SPSS
(version 18.0; SPSS, Inc., Chicago, IL) software package.
Chi-square test and Fisher’s exact test were used for
comparison of dichotomous variables, and Mann–Whitney
U test was used for comparison of continuous variables
between the PET and USG groups. P-values \ 0.05 were
considered statistically significant.
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RESULTS
Over the study period, there was an increasing trend of
ITC detected, with more being discovered in the latter
5 years (2005–2009) when compared with the earlier
5 years (2000–2004) (28 versus 5, respectively). Table 1
presents a comparison of demographic data, history, and
type of nonthyroidal malignancy as well as indication for
imaging between the PET and USG groups. There were
significant differences in age at diagnosis, history of
malignancy, and indication for imaging between the two
groups. The median age in the PET group was significantly
older when compared with the USG group (60 versus
39 years, P = 0.014). In the PET group, seven (31.8%)
patients had their ITC discovered within 6 months of the
diagnosis of the nonthyroidal malignancy (i.e., synchro-
nous tumors), compared with two (18.2%) patients in the
USG group (P = 0.407). Gastrointestinal malignancy was
the most common type of nonthyroidal malignancy in both
groups. None received direct head and neck irradiation as
treatment for their nonthyroidal malignancy. Evaluation for
malignancy was the most frequent indication for imaging
in the PET group, whereas evaluation for a medical con-
dition and health check were equally important indications
in the USG group.
Focal FDG uptake confined to one lobe was found in 21 of
22 patients, while 1 had diffuse focal uptake in the PET
group. Two patients had additional focal uptake in the cer-
vical lymph nodes, and both were later confirmed to have
lymph node metastases requiring lateral neck dissection. The
median SUVmax of hypermetabolic thyroid lesion was 6.3
(range 2.3–34.3). Table 2 presents a comparison of ultraso-
nographic and FNA cytology findings as well as treatment
strategy between the PET and USG groups. On bedside USG,
the median tumor size and the proportion of suspicious
features between the PET and USG groups were similar. The
FNA cytology results were also similar between the two
groups. None had benign cytology (i.e., a false-negative
result). The extent of thyroid resection was similar in the two
groups, but there was a higher rate of CND performance in
the PET group (P = 0.062).
Table 3 presents a comparison of histological findings
between the PET and USG groups. Papillary carcinoma
(PTC) was the most common histological type, accounting
for 20/22 (90.9%) in the PET group and 10/11 (90.9%) in
the USG group. Median tumor size was similar between the
two groups. There was higher incidence of multifocal
tumor in the PET group (P = 0.125). Tumor bilaterality
was significantly more frequent in the PET group when
compared with the USG group (9/20 versus 0/11,
P = 0.04). The median size of these contralateral tumors
was 4 mm (range 1–10 mm). None of the contralateral
tumors were detected on preoperative bedside USG. Of the
nine patients with tumor bilaterality in the PET group,
three had the primary tumor size\1 cm (3 mm, 5 mm, and
6 mm). The incidence of capsular invasion, extrathyroidal
extension, and associated thyroiditis appeared similar in the
two groups. There was a tendency for higher incidence of
cervical lymph node metastases in the PET group
(P = 0.407). Tumors in the PET group had more advanced
stages by the 6th edition TNM system, with half of them
being stage III (P = 0.021). At median follow-up of
18.7 months (range 1.4–107.9 months), in the PET group,
18 patients were alive and free of recurrent disease, 1 died
of metastatic rectal carcinoma 28.2 months after thyroid
resection, and 1 was alive with metastatic carcinoma of
corpus. In the USG group, all were alive and free of
recurrences except for one patient who developed meta-
static PTC in ipsilateral neck lymph nodes 28 months after
the initial thyroid resection.
TABLE 1 comparison of
demographic data, history, and
type of nonthyroidal
malignancy as well as indication
for imaging between the PET
and USG groups
Bold values indicate P \ 0.05
Variable PET group (n = 22) USG group (n = 11) P-value
Age at diagnosis (years, range) 60 (37–79) 39 (23–83) 0.014
Gender (female:male) 16:06 8:03 0.653
History of nonthyroidal malignancy (%) 20 (90.9) 2 (18.2) \0.001
Type of nonthyroidal malignancy (%) 0.298
Gastrointestinal malignancy 8 (36.4) 2 (18.2)
Breast malignancy 6 (27.3) 0
Gynecological malignancy 2 (9.1) 0
Lung malignancy 1 (4.5) 0
Hematological malignancy 2 (9.1) 0
Indication for imaging (%) \0.001
Evaluation for malignancy 20 (90.9) 2 (18.2)
Evaluation for a medical condition 1 (4.5) 5 (45.5)
Health check 1 (4.5) 4 (36.4)
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DISCUSSION
In the present study, although ITC only accounted for
7.2% of all thyroid cancers managed at our institution,
there was a trend towards more cases in the latter 5 years
(2005–2009) relative to the earlier 5 years (2000–2004) (28
versus 5). With the wider availability and greater need for
imaging studies across many medical specialties, this trend
is likely to continue in the future. It is a reasonable
assumption that some of these ITC probably do belong to
the occult microcarcinoma group, and so intervention may
not be necessary as they do not become clinically
TABLE 2 Comparison of
FDG-PET, ultrasonographic,
FNA cytology (FNAC) findings,
and treatment strategy between
the PET and USG groups
a Including taller-than-wide,
macro- or microcalcifications,
irregular margins, and marked
hypoechogenicity
Variable PET group (n = 22) USG group (n = 11) P-value
Ultrasonographic findings
Median size (mm) (range) 13.5 (5–28) 10 (5–15) 0.286
Suspicious featuresa (%) 13 (61.9) 7 (63.6) 0.784
FNAC of thyroid nodule (%) 0.606
Benign 0 (0.0) 0 (0.0)
Inadequate for diagnosis 3 (13.6) 2 (18.2)
Indeterminate 14 (63.6) 8 (72.7)
Malignancy 5 (22.7) 1 (9.1)
Type and extent of resection (%) 1
Total thyroidectomy 20 (90.9) 10 (90.9)
Hemithyroidectomy 2 (9.1) 1 (9.1)
Concomitant neck dissection (%) 0.062
Central neck or level VI 9 (40.9) 0 (0.0)
Ipsilateral lateral neck 3 (13.6) 2 (18.2)
Contralateral lateral neck 0 (0.0) 0 (0.0)
Bilateral neck 1 (4.5) 0 (0.0)
Radioiodine ablation (%) 15 (68.2) 5 (45.5) 0.223
TABLE 3 Comparison of
histological findings between
the PET and USG groups
a Only those who underwent
total thyroidectomy were
included
b AJCC Cancer Staging
Manual38
Bold values indicate P \ 0.05
Histological finding PET group (n = 22) USG group (n = 11) P-value
Histological type (%) 0.687
Papillary carcinoma 20 (90.9) 10 (90.9)
Follicular carcinoma 1 (4.5) 1 (9.1)
Undifferentiated carcinoma 0 (0.0) 0 (0.0)
Hu¨rthle cell carcinoma 1 (4.5) 0 (0.0)
Median tumor size (mm) (range)
Primary tumor 13 (3–30) 10 (1–18) 0.264
Contralateral lobea 4 (1–10) Not applicable –
Tumor multifocality (%) 10 (45.5) 2 (18.2) 0.125
Tumor bilateralitya (%) 9 (45.0) 0 (0.0) 0.04
Extrathyroidal extension (%) 8 (36.4) 4 (36.4) 0.653
Capsular invasion (%) 8 (36.4) 2 (18.2) 0.284
Lymph node metastases (%) 7 (31.8) 2 (18.2) 0.407
Associated thyroiditis (%) 5 (22.7) 2 (18.2) 0.813
TNM tumor stagingb (%) 0.021
I 5 (22.7) 8 (72.7)
II 6 (27.3) 1 (9.1)
III 11 (50.0) 2 (18.2)
IV 0 (0.0) 0 (0.0)
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significant carcinoma in the patient’s lifetime. However, it
remains unresolved how best to predict which ones will
progress and which ones to intervene early. This unre-
solved problem was highlighted in several recent
publications.3,25–28 As a consequence, management of ITC,
particularly subcentimeter carcinoma, remains controver-
sial, with some investigators even advocating pure
observation with regular USG surveillance as primary
treatment, even though most would perform surgical
resection.27,28 It is also important to note that not all ITC
behave in the same benign manner and that some should be
managed in much the same way as clinically significant
carcinomas.29,30 The purpose of the present study is to
examine the clinicopathological features of ITC based on
the imaging modality. We hypothesized that ITC detected
by FDG-PET/CT might have more aggressive histological
features than those detected by other means, as previous
studies have shown that primary nonincidental carcinomas
as well as their metastases detected by FDG-PET/CT ten-
ded to be less well differentiated, possessed more
aggressive histological features, and behaved more
aggressively.20,21
When the clinicopathological features of ITC were
compared between the PET and USG groups, one of the
most significant findings was that those in the PET group
had significantly higher frequency of tumor bilaterality.
This was despite the fact that both groups had comparable
tumor size as well as some histological findings such as
tumor multifocality, extrathyroidal extension, capsular
invasion, and lymph node metastases. In terms of surgical
management, this might have important implications, par-
ticularly for surgeons who follow the recommendation in
the 2009 American Thyroid Association (ATA) guide-
lines.31 As the revised ATA guidelines recommend
hemithyroidectomy for tumor size \1 cm, if one were to
follow this recommendation, three of the nine FDG-PET/
CT-detected ITC with tumor bilaterality would have
otherwise undergone hemithyroidectomy instead of total
thyroidectomy and, in so doing, a tumor focus would have
been left behind in the contralateral lobe. Although the
long-term outcome of leaving small contralateral tumor
focus after hemithyroidectomy remains not well under-
stood, the possibility of locoregional recurrence remains.
This was made worse by the fact that the foci in the con-
tralateral lobe, despite some being as large as 10 mm,
could not be picked up by preoperative USG. Perhaps this
reflects some of the limitations related to preoperative
imaging modalities, particularly bedside USG. Possible
reasons for failure of USG in detecting contralateral dis-
ease include small size (\5 mm), lesion without suspicious
features, and operator dependency. In our opinion, given
the high frequency of tumor bilaterality and the relative
inability of preoperative imaging to detect contralateral
tumor focus, perhaps total thyroidectomy should be con-
sidered in FDG-PET/CT-detected ITC even for tumor size
\10 mm. It was also interesting to note that all nine
patients with tumor bilaterality in the PET group had a
single uptake on the ITC side only, and the only patient
with diffuse uptake did not have tumor bilaterality. This
suggested that FDG-PET/CT was relatively inaccurate at
predicting tumor bilaterality. This might be related to the
fact that these contralateral tumors tend to be too small in
size for detection and FDG-PET/CT does have limitations
with spatial resolution and partial volume effects.32
Another alternative reason might have been related to
mutational profile differences between the tumor foci in the
opposite lobe, with some more preferentially taking up
FDG nuclide. This notion was supported by two studies
demonstrating genetic heterogeneity between different
tumor foci within the same gland when RET/PTC rear-
rangement and BRAF mutations were evaluated.33,34 In
addition, study of pattern of X-chromosome inactivation of
multiple distinct foci of well-differentiated thyroid multi-
focal PTC revealed that individual tumor foci in patients
with multifocal PTC often arose as de novo tumors.35
Given that tumor bilaterality and multifocality are not
distinct biological processes, one possible reason for the
higher incidence of bilaterality but not multifocality in the
PET group might be due to the small number of patients in
each group.
While patients in the PET group were significantly older
than the USG group (P = 0.014), patients with older age
did not have higher incidence of contralateral tumors
(P = 0.555). Tumor bilaterality was also not related to
positive history of nonthyroidal malignancy (P = 0.156).
The other significant finding was that, despite similar
tumor size, those in the PET group were more advanced in
AJCC/UICC (American Joint Committee on Cancer/Inter-
national Union against Cancer) TNM tumor stage. This
finding seemed to concur with our initial postulation that
ITC by FDG-PET/CT tends to behave more aggressively.
All patients (n = 5) who underwent lateral neck dissection
in both groups had suspicious lateral neck lymph nodes
preoperatively, and all ended up having histologically
proven lymph node metastases. In this study, there were no
patients with suspicious central neck lymph nodes on
preoperative bedside USG, but it is known that lymph node
metastases in the central compartment do not always
appear abnormal preoperatively on imaging in many
patients.36 The decision regarding CND performance was
made intraoperatively. There could have been possibility of
tumor upstaging in the PET group resulting from more
concomitant CND being done in this group. As was shown
previously, routine prophylactic CND tends to upstage
tumors by upgrading nodal status from pN0 to pN1a.37 The
authors felt this possibility was unlikely, since prophylactic
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CND was not performed throughout the study period, but
because the distinction between prophylactic and thera-
peutic CND still remains unclear at times, the possibility of
tumor upstaging could not be completely ruled out.
Due to the retrospective nature of the present study,
there are potential selection biases. One such bias was that
there were more patients in the PET group with history of
nonthyroidal malignancy, which may have rendered the
two groups less comparable. Also some ITC with dissem-
inated nonthyroidal malignancy might have been excluded,
as they would not have undergone thyroid resection
because of poor overall prognosis, although one patient in
the PET group did die of metastatic rectal carcinoma. In
addition, there were significant advances in PET scanner
technology over the study period, and this might account
for the increase in detection of thyroid incidentaloma in the
latter study period (2005–2009). Although unlikely, the
authors could not exclude the possibility that some of these
biases may account for some histological differences in the
two groups.
CONCLUSIONS
Those ITC detected by FDG-PET/CT had significantly
higher frequency of tumor bilaterality than those detected by
USG. Given this high frequency of 45% and the inability of
current imaging studies to detect these contralateral foci,
total thyroidectomy should be recommended for ITC
detected by FDG-PET/CT even for tumor size\10 mm.
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